MORC3 and calcinosis: Patients with positive anti‐NXP2 antibodies often experience more significant muscle weakness rather than skin involvement and are more likely to exhibit symptoms such as myalgia, subcutaneous edema, dysphagia, calcinosis, and even distal muscle weakness [12, 13].